Convatec Wound

  • Home
  • Convatec Wound

Convatec Wound Contact information, map and directions, contact form, opening hours, services, ratings, photos, videos and announcements from Convatec Wound, Medizin und Gesundheit, .

At Convatec, is our promise to patients & healthcare providers, as we deliver pioneering trusted medical solutions to improve the lives we touch. .

💜 Performance You Can Rely On.​At , during our symposium “A Year of Healing”, we discussed what makes ConvaFoam™ unique...
13/05/2026

💜 Performance You Can Rely On.​

At , during our symposium “A Year of Healing”, we discussed what makes ConvaFoam™ unique.¹​

The only foam combining three technologies in one dressing:​
✔️Hydrofiber​
✔️Superabsorber​
✔️ConvaTac™​

Early NHS data demonstrated that ConvaFoam™ achieved 98% of clinical objectives, significantly reduced dressing changes and decreased overall resource use and spend. ²​

During the session, Shauna Roberts, BSc (Hons), Advanced Wound Care Technical Lead, shared the research and development behind ConvaFoam™ innovation. ¹​

Read more here: https://brnw.ch/21x2soh ​

European Wound Management Association - EWMA

References:​
¹ Convatec. A Year of Healing: Advancing wound care with a next-generation foam dressing. EWMA 2026 ConvaFoam™ Symposium Programme Information. ​

² Hughes M, Wilkins J, Fisher J, Rodger R. Early outcomes of implementing a new multilayer foam dressing in an acute setting: assessing clinical and financial impact through value-based procurement. EWMA 2026 Abstract [1196].

AP-79504-GBL-ENG-v1

Join us at the 21st Malvern Diabetic Foot Conference where we will be hosting a symposium on ConvaNiox™, our multimodal,...
11/05/2026

Join us at the 21st Malvern Diabetic Foot Conference where we will be hosting a symposium on ConvaNiox™, our multimodal, nitric oxide-generating dressing for diabetic foot ulcers (DFUs).¹​

Chaired by Dr Chris A. Manu and joined by Daniel Metcalf our session will begin with an explanation of the multimodal features of ConvaNiox™ that have contributed to the superior healing outcomes compared to standard of care in an RCT.²

A post-hoc analysis will present further data on ulcer duration, concomitant antibiotic usage and infection status, highlighting potential use strategies for ConvaNiox™. ​

Lastly, we’ll hear about experiences using ConvaNiox™ that show its strength in tackling a range of challenging DFUs. ​

📍Join us at Malvern on the 14th of May for the full session ​

🔗 Learn more about ConvaNiox™ here: https://brnw.ch/21x2nSN

​

References: ​
1. ConvaNiox Claims Summary, RPT-088112 v2.0. Data on file. Convatec Inc., 2025. ​

2. Edmonds ME, et al. Multicenter, randomized controlled, observer-blinded study of a nitric oxide generating treatment in foot ulcers of patients with diabetes—ProNOx1 study. Wound Repair Regen. 2018;26:228–237. ​

AP-79967-GBL-ENG-v1

11/05/2026

What a week at đź’ś

From inspiring conversations and shared learning to innovation on the stand and moments that reminded us why this community matters, EWMA 2026 was truly energising.

It was a privilege to connect with clinicians, partners, speakers, and innovators from across the wound care community - all united by a shared commitment to improving outcomes for patients worldwide. From insightful discussions at our booth to meaningful exchanges throughout the congress, our team left feeling motivated by the passion, collaboration, and expertise on display.

Thank you to everyone who engaged with us throughout the week and continues to move wound care forward every day. We’re proud to be part of this community and the collective commitment to advancing care together.

Here’s a look back at some of our highlights from EWMA 2026.

European Wound Management Association - EWMA

At , we hosted a 60-minute session exploring a novel approach to diabetic foot ulcer management.​During the session, we...
11/05/2026

At , we hosted a 60-minute session exploring a novel approach to diabetic foot ulcer management.​

During the session, we explored the science behind ConvaNiox™, summarised laboratory data on its multimodal features and shared the randomised control trial results showing ConvaNiox™’s superior healing outcomes compared to standard of care dressings.¹​

We also heard real-world experiences from clinicians across Europe, alongside data demonstrating the cost-effectiveness of this innovative approach.²​

Thank you to our Chair, Prof José Luis Lázaro-Martínez, and faculty Prof Alberto Piaggesi, and Daniel Metcalf for leading such an important discussion.​

"We are thrilled to see the patients that have recently benefited from ConvaNiox from Italy and Spain. Presented by world-renowned diabetic foot ulcer experts, these cases build on our randomized controlled trial data, while highlighting the clinical benefits of the multimodal features of ConvaNiox™" - Daniel Metcalf

Read more here: https://brnw.ch/21x2nmF



References: ​
1. Edmonds ME, et al. Multicenter, randomized controlled, observer-blinded study of a nitric oxide generating treatment in foot ulcers of patients with diabetes-ProNOx1 study. Wound Repair Regen. 2018;26(2):228-237​

2. Convatec. A Novel, Multimodal Nitric Oxide-Generating Dressing for Superior Clinical Outcomes in Diabetic Foot Ulcers. EWMA 2026 ConvaNiox™ Symposium Outline. ​

AP-80022-GBL-ENG-v1 (v1.0)

In December 2024, eight of the world’s leading DFU (diabetic foot ulcer) experts gathered in London ​to discuss a better...
10/05/2026

In December 2024, eight of the world’s leading DFU (diabetic foot ulcer) experts gathered in London ​to discuss a better future for DFU care.

Among the key messages of this round table meeting were²: ​

• How DFUs remain an urgent and highly burdensome aspect of diabetes for patients due​ to infection, hospitalisation and amputation. ​

• How DFU treatment is in desperate need of further innovation to curb persistent infections ​and improve healing outcomes. ​

• How proactivity in treatment, better education, new patient metrics and simplicity in ​guidelines alongside novel innovations like ConvaNiox™ could be key to improving future ​DFU care. ​

Read the article today to learn more about the discussions shaping the future of DFU care: https://brnw.ch/21x2mvS

​References:

1. This article is based on the first roundtable meeting, part of a wider multi-stage dialogue, of ​leading global experts in DFU care. ​

2. Armstrong DG, et al. Global expert dialogue on diabetic foot ulcer care: driving urgency, ​innovation, and collaboration. J Wound Manage. 2026;27(1):105-108. ​

*All authors serve as consultants to Convatec.​

AP-79742-GBL-ENG-v1

At , Convatec is showcasing the breadth, depth and momentum behind our strongest-ever Advanced Wound Care innovation pi...
07/05/2026

At , Convatec is showcasing the breadth, depth and momentum behind our strongest-ever Advanced Wound Care innovation pipeline.

Tanja Dormels, President of Advanced Wound Care, joined us on site, reinforcing why this moment matters and how evidence‑led innovation, patient‑centred design, and 30 years of Hydrofiber® technology are coming together to meaningfully advance healing and reshape clinical practice.

From next‑generation foam and nitric oxide‑generating dressings to Wound Hygiene and new clinical and real‑world evidence across hard‑to‑heal wounds, EWMA is an important moment to demonstrate how Convatec is leading the industry to meet the needs of patients and healthcare professionals worldwide.

Explore the insights and come visit us at booth F10 to continue the conversation at European Wound Management Association - EWMA

What a fantastic Day 2 at 💜​Today was filled with insightful discussions, lots of inspiring collaboration and meaningf...
07/05/2026

What a fantastic Day 2 at 💜​

Today was filled with insightful discussions, lots of inspiring collaboration and meaningful conversations around wound care.​

A key highlight for us was our symposium: A Year of Healing: Advancing wound care with a next-generation foam dressing.​

It was a privilege to share the science, evidence and real-world impact behind ConvaFoam™ with the EWMA community.​

"Its been real exciting to be able to bring the R&D to the clinicians today and show that what they are asking us for, we are listening to and we are trying to deliver" - Shauna Roberts

Thank you to our incredible speakers:​

Dr. Przemysław Lipinski MD, PhD, ARGO​

Shauna Roberts, BSc (Hons), Advanced Wound Care Technical Lead, Convatec​

Chaired by Dale Copson MSc, BSc (Hons) RN. Senior Global Medical Education Specialist, Convatec. ​

European Wound Management Association - EWMA

Day 2: We’re at today!​It’s great to be back and we’re excited to share with you our latest innovations and research.​...
07/05/2026

Day 2: We’re at today!​

It’s great to be back and we’re excited to share with you our latest innovations and research.​​

Join us this afternoon at 16:15-17:15 in the Session room: 5C, for our symposium:​

“A Year of Healing: Advancing wound care with a next-generation foam dressing.”​

Hear from Dr Przemysław Lipinski, MD, PhD, ARGO, Dale Copson, MSc, BSc (Hons) RN. Senior Global Medical Education Specialist for Advanced Wound Care, Convatec and Shauna Roberts, BSc (Hons), Advanced Wound Care Technical Lead, Convatec, as they explore the science and clinical impact of ConvaFoam™.​

European Wound Management Association - EWMA

AP-79488-GBL-ENG-v1

06/05/2026

Diabetic foot ulcers demand more than conventional solutions.¹​

ConvaNiox™ is designed with a sophisticated, multimodal architecture to help address the complex challenges of DFU management.² ³​

Powered by nitric oxide, its intelligent design supports:​

• Antimicrobial and antibiofilm protection​
• Effective exudate absorption and moisture regulation​
• Conditions that support wound healing processes​

A new blueprint for DFU care is emerging.​

Explore the science behind ConvaNiox™: https://brnw.ch/21x2fI0

​

References:​

1. Coye TL, et al. Healing of diabetic neuropathic foot ulcers receiving standard treatment in randomised controlled trials: A random effects meta-analysis. Wound Repair Regen. 2025;33(1):e13237.​

2. Edmonds ME, et al. Multicenter, randomized controlled, observer-blinded study of a nitric oxide generating treatment in foot ulcers of patients with diabetes-ProNOx1 study. Wound Repair Regen. 2018;26(2):228-237.​

3. ConvaNiox Claims summary. RPT-088112 v2.0, 2026, Data on file, Convatec Inc.​

AP-79246-GBL-ENG-v1

An incredible Day 1 at ​We’ve enjoyed connecting with so many passionate clinicians, partners and innovators. ​Here ar...
06/05/2026

An incredible Day 1 at ​
We’ve enjoyed connecting with so many passionate clinicians, partners and innovators. ​

Here are a few snapshots from Day 1. 📸​

Visit us at booth F10 where we’ll have product demonstrations and top tips from our Wound Hygiene team.​

06/05/2026

Day 1: Workshop Highlights 👇​
​
At our Convatec Advanced Wound Care teams are leading hands-on workshops focused on real-world challenges – sharing expertise, exploring new techniques, and turning insight into action. ​
​
Through practical discussion and collaboration, we’re helping drive conversations that matter most in advanced wound care.​
​
Join our experts at booth F10 to keep the conversation going.​

Take a look at the ConvaNiox workshop below 👇

European Wound Management Association - EWMA

Address


28307

Website

Alerts

Be the first to know and let us send you an email when Convatec Wound posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Shortcuts

  • Want your practice to be the top-listed Clinic?

Share